A meta-analysis of quality-of-life estimates for stroke.
about
An economic model of long-term use of celecoxib in patients with osteoarthritisEconomic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the Netherlands.Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary interventionCarotid artery stenosis: cost-effectiveness of assessment of cerebrovascular reserve to guide treatment of asymptomatic patients.Cost-effectiveness of anticoagulation in patients with nonvalvular atrial fibrillation with edoxaban compared to warfarin in Germany.The Quit Benefits Model: a Markov model for assessing the health benefits and health care cost savings of quitting smoking.Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular eventsIs primary angioplasty cost effective in the UK? Results of a comprehensive decision analysis.Twenty-four-hour ambulatory blood pressure monitoring in hypertension: an evidence-based analysis.Is Meta-Analysis for Utility Values Appropriate Given the Potential Impact Different Elicitation Methods Have on Values?The burden of stroke in the Netherlands: estimating quality of life and costs for 1 year poststroke.Cost-Effectiveness of Carotid Plaque MR Imaging as a Stroke Risk Stratification Tool in Asymptomatic Carotid Artery Stenosis.Effects of art therapy using color on purpose in life in patients with stroke and their caregivers.Cost-effectiveness of retreatment with varenicline after failure with or relapse after initial treatment for smoking cessationA review and meta-analysis of prostate cancer utilities.Health-state utilities in liver disease: a systematic review.Cost-effectiveness of 7-day-Holter monitoring alone or in combination with transthoracic echocardiography in patients with cerebral ischemiaA review and meta-analysis of utility values for lung cancer.Health-state utility values in breast cancer.A meta-analysis of health state valuations for people with diabetes: explaining the variation across methods and implications for economic evaluation.Stop the clots, but at what cost? Pharmacoeconomics of dabigatran etexilate for the prevention of stroke in subjects with atrial fibrillation: a systematic literature review.Sequential value-of-information assessment for prospective drug safety monitoring using claims databases: the comparative safety of prasugrel v. clopidogrel.A systematic literature review of cardiovascular event utilities.Sourcing quality-of-life weights obtained from previous studies: theory and reality in Korea.Utility Values for Adults with Unipolar Depression: Systematic Review and Meta-Analysis.A Review and Meta-analysis of Colorectal Cancer Utilities.Cost effectiveness of renal denervation therapy for the treatment of resistant hypertension in the UK.Re-treatment with varenicline is a cost-effective aid for smoking cessation.A Systematic Review of Cardiovascular Outcomes-Based Cost-Effectiveness Analyses of Lipid-Lowering Therapies.Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan.Cost effectiveness of rivaroxaban for stroke prevention in German patients with atrial fibrillation.Joint assessment of intended and unintended effects of medications: an example using vascular endothelial growth factor inhibitors for neovascular age-related macular degeneration.A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction.Optimizing statin treatment decisions for diabetes patients in the presence of uncertain future adherence.Estimated quality-adjusted life-year associated with the degree of activities of daily living in patients with Alzheimer's disease.Uncertainty on the effectiveness and safety of rivaroxaban in premenopausal women with atrial fibrillation: empirical evidence needed.Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden.Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model.When is carotid angioplasty and stenting the cost-effective alternative for revascularization of symptomatic carotid stenosis? A Canadian health system perspective.Smoking cessation treatment and outcomes patterns simulation: a new framework for evaluating the potential health and economic impact of smoking cessation interventions.
P2860
Q28218005-B87819BC-A783-4E79-85FE-A3775DAEE67FQ34004770-FB0D9E19-7C18-4AD7-B6B4-56C8EA972385Q34166239-4C73DAD1-6B8F-432E-B2C2-3259AF063D66Q35100438-4448BD05-BB9F-42C6-9BE1-6750441CA7F2Q35234175-DF0F9D94-4427-4192-BA4F-4E4C192540E3Q35633096-C2FB9751-E7BB-48EC-9652-4636E6583026Q35752981-0A4C2D28-DE19-4E31-B518-DDF92DC3C2FFQ36025741-FE524C58-C16E-4D84-BAF1-A70E4DB777E2Q36039995-BFFB3B5C-FFEA-4375-9FE1-F6D23DFE07DDQ36167435-35651720-A457-4AB5-A961-CBD30BB3BDB9Q36329204-FDB1B817-C770-4889-895B-D163FE376926Q36354380-0BCADA8F-9C59-4384-B072-4AC5D2C327BEQ36463898-14B9EA51-4DA2-4F34-AECA-083D7C951F02Q36486726-9B6A29D9-774D-4A7A-96F9-FC0665E6A5EBQ36821787-DEF860F4-84BE-4470-974D-44B0FE269877Q37142994-7152D056-BAC4-43B6-B6A5-2CDF6B5B617EQ37303759-8E894849-C0B2-4CDF-87BA-00DCBDC90AECQ37744304-0DB63C3C-0C1A-4E9B-8532-BFA5712CA3BFQ37800481-EA0C39B7-FB16-44EA-AB6E-4BB571831601Q37862622-F2E8687D-1A1E-4317-885F-0B5ECCD09B01Q38080912-AA0AE92A-2353-459F-B629-117051D660FCQ38127002-256B580A-DC45-4094-AF53-A57D2FE55327Q38157041-F8200FAB-3327-457B-A0FB-41AD6ECD05E5Q38191873-9AA23C73-CA51-41D5-8652-4716CFF97657Q38201656-F7D4AB12-C25E-4C7E-B104-C34CE34EA049Q38218009-D8649AEF-6953-408A-82C4-3E27BD1E7E3AQ38236292-0288AF49-0B4F-40BB-BAD2-DB905E0B1195Q38984010-C1879C84-0C8E-4401-AEC4-EA0B902A8B2FQ38992196-7E65AA9C-442E-4271-AFC5-90BB7A0BE34DQ39091796-8AEEB3C3-EF6F-49F7-8770-D58B0361700CQ39096950-9FF36F7E-8177-42E2-8094-2A0AF49D7CC8Q39566377-5C3F6B83-3633-4BBF-BF9C-A5247122C626Q39709613-8C10CE6B-A1D2-4777-B7AA-87EBB5B06742Q39755456-94578439-08E8-4A9D-BF8E-7D6A01976C20Q41862787-9FABF64B-E95C-4E4E-B56B-5322947E652BQ42377391-FED4BB05-2FE6-4EFD-939C-1FE516027D28Q43411786-F4A1A191-8CC3-4F21-8A60-DFC3BA06E59FQ43637595-1AAB297F-7E5D-4FE4-A17E-801BF5C11A14Q43716111-B1FBB269-C709-4F02-88B8-F55DDBB43618Q43781923-AF164F94-CB3A-45C6-9757-7ACE3397EDD6
P2860
A meta-analysis of quality-of-life estimates for stroke.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
A meta-analysis of quality-of-life estimates for stroke.
@ast
A meta-analysis of quality-of-life estimates for stroke.
@en
type
label
A meta-analysis of quality-of-life estimates for stroke.
@ast
A meta-analysis of quality-of-life estimates for stroke.
@en
prefLabel
A meta-analysis of quality-of-life estimates for stroke.
@ast
A meta-analysis of quality-of-life estimates for stroke.
@en
P1433
P1476
A meta-analysis of quality-of-life estimates for stroke.
@en
P2093
Tammy O Tengs
Ting H Lin
P304
P356
10.2165/00019053-200321030-00004
P577
2003-01-01T00:00:00Z
P6179
1023312597